|
95 Companies |
|
180 Products |
|
180 Products |
|
97 Mechanisms of Action |
|
2 Trials |
|
2111 News |
|
| «12...4567891011121314...4243» |
- ||||| Enrollment change: AMPACT2: AM-101 in the Treatment of Post-Acute Tinnitus 2 (clinicaltrials.gov) - Mar 24, 2016
P3, N=600, Recruiting, Sponsor: Auris Medical AG
N=300 --> 600
- Trial primary completion date: A Randomised Controlled Trial Comparing Bone Anchored Hearing Aid With Bonebridge (clinicaltrials.gov) - Mar 23, 2016
P=N/A, N=60, Recruiting, Sponsor: Ninewells Hospital
N=300 --> 600 Trial primary completion date: Jan 2017 --> Dec 2017
- ||||| Keyzilen (esketamine) / Altamira Therap
Enrollment closed: TACTT2: AM-101 in the Treatment of Acute Tinnitus 2 (clinicaltrials.gov) - Mar 22, 2016
P3, N=332, Active, not recruiting, Sponsor: Auris Medical, Inc.
Trial primary completion date: Jan 2017 --> Dec 2017 Completed --> Active, not recruiting
- Trial primary completion date: SBRCTHILARBA: Efficacy Study of Homeopathic Medicines in Treatment of Allergic Rhinitis and/or Induced Bronchial Asthma (clinicaltrials.gov) - Mar 22, 2016
P=N/A, N=100, Recruiting, Sponsor: Mahesh Bhattacharyya Homoeopathic Medical College and Hospital
Completed --> Active, not recruiting Trial primary completion date: Mar 2016 --> Mar 2017
- |||||| Enrollment open, Trial initiation date, Trial primary completion date: Efficacy and Safety of Combination of Brompheniramine and Phenylephrine for the Symptoms Relief of Rhinitis (clinicaltrials.gov) - Mar 18, 2016
P3, N=538, Recruiting, Sponsor: Ache Laboratorios Farmaceuticos S.A.
Trial primary completion date: Mar 2016 --> Mar 2017 Not yet recruiting --> Recruiting | Initiation date: Sep 2011 --> Aug 2014 | Trial primary completion date: Mar 2012 --> Dec 2016
- Biomarker, Enrollment closed: NCGENES: North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing (clinicaltrials.gov) - Mar 18, 2016
P=N/A, N=645, Active, not recruiting, Sponsor: University of North Carolina, Chapel Hill
Not yet recruiting --> Recruiting | Initiation date: Sep 2011 --> Aug 2014 | Trial primary completion date: Mar 2012 --> Dec 2016 Recruiting --> Active, not recruiting
- ||||||| Keyzilen (esketamine) / Altamira Therap
Trial completion: TACTT2: AM-101 in the Treatment of Acute Tinnitus 2 (clinicaltrials.gov) - Mar 18, 2016
P3, N=332, Completed, Sponsor: Auris Medical, Inc.
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||||||| Trial completion, Trial initiation date, Trial primary completion date: Efficacy and Safety of Combination of Brompheniramine and Phenylephrine for the Symptoms Relief of Rhinitis (clinicaltrials.gov) - Mar 16, 2016
P3, N=167, Completed, Sponsor: Ache Laboratorios Farmaceuticos S.A.
Recruiting --> Completed Not yet recruiting --> Completed | Initiation date: Sep 2011 --> Jul 2014 | Trial primary completion date: Mar 2012 --> Oct 2014
- azithromycin / Generic mfg.
Trial completion: Efficacy of Azithromycin Prophylaxis in Preventing Recurrent Acute Sinusitis in Children (clinicaltrials.gov) - Mar 16, 2016
P=N/A, N=40, Completed, Sponsor: Mahidol University
Not yet recruiting --> Completed | Initiation date: Sep 2011 --> Jul 2014 | Trial primary completion date: Mar 2012 --> Oct 2014 Active, not recruiting --> Completed
- Trial completion, Enrollment change: Validation of a Revised Version of the Danish McGill Ingestive Skills Assessment (clinicaltrials.gov) - Mar 16, 2016
P=N/A, N=328, Completed, Sponsor: Metropolitan University College
Active, not recruiting --> Completed Recruiting --> Completed | N=500 --> 328
- Trial completion, Trial primary completion date: A Post-Market Clinical Trial for Access and Visualization of the Oropharynx, Hypopharynx and Larynx During Transoral Procedures (clinicaltrials.gov) - Mar 16, 2016
P=N/A, N=80, Completed, Sponsor: Medrobotics Corporation
Recruiting --> Completed | N=500 --> 328 Recruiting --> Completed | Trial primary completion date: Mar 2016 --> Dec 2015
- Tasigna (nilotinib) / Novartis, Inhibikase
Enrollment change, Trial termination: A Study of Nilotinib in Growing Vestibular Schwannomas (clinicaltrials.gov) - Mar 14, 2016
P2, N=2, Terminated, Sponsor: University Health Network, Toronto
Recruiting --> Completed | Trial primary completion date: Mar 2016 --> Dec 2015 N=90 --> 2 | Recruiting --> Terminated; Study PI passed away We had trouble recruiting for the drug arm
- dexamethasone / Generic mfg., dexamethasone injection / Generic mfg.
Enrollment change, Trial termination, Surgery: Effect of Intravenous Corticosteroid Injections on Dysphagia After Cervical Spine Surgery (clinicaltrials.gov) - Mar 14, 2016
P3, N=4, Terminated, Sponsor: New York University School of Medicine
N=90 --> 2 | Recruiting --> Terminated; Study PI passed away We had trouble recruiting for the drug arm N=80 --> 4 | Recruiting --> Terminated
- cisplatin / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC (clinicaltrials.gov) - Mar 11, 2016
P1, N=3, Active, not recruiting, Sponsor: Virginia Commonwealth University
N=80 --> 4 | Recruiting --> Terminated Suspended --> Active, not recruiting | N=15 --> 3 | Trial primary completion date: Jan 2017 --> Apr 2016
- Trial completion: Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo (clinicaltrials.gov) - Mar 11, 2016
P2, N=209, Completed, Sponsor: Keimyung University Dongsan Medical Center
Suspended --> Active, not recruiting | N=15 --> 3 | Trial primary completion date: Jan 2017 --> Apr 2016 Recruiting --> Completed
- Trial primary completion date: Does Tympanometry Predict Antibiotic Usage in Acute Otitis Media? (clinicaltrials.gov) - Mar 10, 2016
P=N/A, N=137, Recruiting, Sponsor: University of Alberta
Recruiting --> Completed Trial primary completion date: Oct 2016 --> Oct 2017
- Epstein-Barr Virus Specific Immunotherapy - Dana / Farber Cancer Institute
Trial primary completion date: Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma (clinicaltrials.gov) - Mar 9, 2016
P=N/A, N=10, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Oct 2016 --> Oct 2017 Trial primary completion date: Jan 2016 --> Jun 2016
- | Trial completion, Enrollment change, Trial primary completion date: Littlears Auditory Questionnaire: Validation Study in CI Children (clinicaltrials.gov) - Mar 9, 2016
P=N/A, N=31, Completed, Sponsor: Med-El Corporation
Trial primary completion date: Jan 2016 --> Jun 2016 Active, not recruiting --> Completed | N=40 --> 31 | Trial primary completion date: Jan 2017 --> Feb 2016
- Trial completion: tRNS-tin: Daily Bi-temporal Transcranial Random Noise Stimulation in Tinnitus (clinicaltrials.gov) - Mar 7, 2016
P=N/A, N=30, Completed, Sponsor: University of Regensburg
Active, not recruiting --> Completed | N=40 --> 31 | Trial primary completion date: Jan 2017 --> Feb 2016 Recruiting --> Completed
- Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial primary completion date: Effect of Vocal Exercise After Botulinum Toxin Injection for Spasmodic Dysphonia (clinicaltrials.gov) - Mar 5, 2016
P=N/A, N=8, Terminated, Sponsor: New York University School of Medicine
Recruiting --> Completed Trial primary completion date: Dec 2015 --> May 2013
- everolimus / Generic mfg., erlotinib / Generic mfg.
Enrollment change, Trial withdrawal: Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy (clinicaltrials.gov) - Mar 5, 2016
P1, N=0, Withdrawn, Sponsor: Fox Chase Cancer Center
Trial primary completion date: Dec 2015 --> May 2013 N=40 --> 0 | Terminated --> Withdrawn
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer (clinicaltrials.gov) - Mar 5, 2016
P2, N=24, Active, not recruiting, Sponsor: Fox Chase Cancer Center
N=40 --> 0 | Terminated --> Withdrawn Recruiting --> Active, not recruiting | N=43 --> 24 | Trial primary completion date: Feb 2016 --> Mar 2015
- Trial completion, Enrollment change: EMA-Defined Tinnitus Subgroups (clinicaltrials.gov) - Mar 2, 2016
P=N/A, N=40, Completed, Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting | N=43 --> 24 | Trial primary completion date: Feb 2016 --> Mar 2015 Recruiting --> Completed | N=1250 --> 40
- Trial primary completion date: Interest of Narrow Band Imaging in Detection of Upper Aerodigestive Cancers (clinicaltrials.gov) - Feb 29, 2016
P=N/A, N=87, Recruiting, Sponsor: University Hospital, Toulouse
Recruiting --> Completed | N=1250 --> 40 Trial primary completion date: Jan 2016 --> Dec 2016
- Trial primary completion date: Acoustic Stimulation Paired With Body and Cortical Stimulation for Modulating Tinnitus (clinicaltrials.gov) - Feb 29, 2016
P=N/A, N=10, Recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Trial primary completion date: Jan 2016 --> Dec 2016 Trial primary completion date: May 2016 --> Dec 2016
- ||||||| levofloxacin / Generic mfg.
Trial completion: Levofloxacin In The Treatment Of Children With Recurrent And/or Persistent Acute Otitis Media (clinicaltrials.gov) - Feb 27, 2016
P3, N=1643, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Trial primary completion date: May 2016 --> Dec 2016 No longer recruiting --> Completed
- ||||||| levofloxacin / Generic mfg.
Trial completion: A Study of the Effectiness and Safety of Levofloxacin in Treating Children With a Rapid and Severe Onset of Infection and Inflammation of the Middle Ear That is Difficult to Treat (clinicaltrials.gov) - Feb 27, 2016
P3, N=206, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
No longer recruiting --> Completed No longer recruiting --> Completed
- Enrollment change, Trial withdrawal, Trial primary completion date: Randomized Trial Comparing Partial Resection of Inferior Turbinate(PRIT) and Radiofrequency Ablation(RFA) for Inferior Turbinate Reduction (clinicaltrials.gov) - Feb 27, 2016
P=N/A, N=0, Withdrawn, Sponsor: Weill Medical College of Cornell University
No longer recruiting --> Completed N=80 --> 0 | Terminated --> Withdrawn | Trial primary completion date: Jul 2009 --> Mar 2009
- astegolimab (RG 6149) / Amgen, Roche
Enrollment closed, Enrollment change: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps (clinicaltrials.gov) - Feb 26, 2016
P1, N=41, Active, not recruiting, Sponsor: Amgen
N=80 --> 0 | Terminated --> Withdrawn | Trial primary completion date: Jul 2009 --> Mar 2009 Recruiting --> Active, not recruiting | N=84 --> 41
- Trial completion: Effectiveness of Early Physical Therapy Intervention for Patients With Dizziness After a Sports-Related Concussion (clinicaltrials.gov) - Feb 26, 2016
P=N/A, N=41, Completed, Sponsor: Walsh University
Recruiting --> Active, not recruiting | N=84 --> 41 Recruiting --> Completed
- lidocaine 5% / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Commercial Lidocaine Patch as a Treatment for Ear-ringing (clinicaltrials.gov) - Feb 26, 2016
P0, N=30, Completed, Sponsor: University of California, Davis
Recruiting --> Completed Recruiting --> Completed | N=44 --> 30 | Trial primary completion date: Dec 2014 --> Aug 2015
- sodium valproate / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Metastases: Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Feb 23, 2016
P2, N=14, Completed, Sponsor: Instituto do Cancer do Estado de S
Recruiting --> Completed | N=44 --> 30 | Trial primary completion date: Dec 2014 --> Aug 2015 Active, not recruiting --> Completed | N=40 --> 14 | Trial primary completion date: Sep 2016 --> Nov 2014
- azithromycin / Generic mfg.
Trial termination: PASS Study To Evaluate The Potential Of Zithromax To Cause Ocular Problems In Pediatric Patients (clinicaltrials.gov) - Feb 18, 2016
P2, N=8, Terminated, Sponsor: Pfizer
Active, not recruiting --> Completed | N=40 --> 14 | Trial primary completion date: Sep 2016 --> Nov 2014 Completed --> Terminated; See Termination Statement in the Detailed Description below
- cilostazol / Generic mfg.
Enrollment change, Trial termination: Effect of Renexin Tablet in Patients With Recurrent Vestibulopathy (clinicaltrials.gov) - Feb 17, 2016
P3, N=26, Terminated, Sponsor: Jong Woo Chung
N=72 --> 26 | Recruiting --> Terminated; Participant enrollment is much delayed. The whole design needs to be revised.
- Trial completion, Enrollment change, Trial primary completion date: CAPHA: Central Auditory Processing and the Use of Hearing Aids (clinicaltrials.gov) - Feb 17, 2016
P=N/A, N=27, Completed, Sponsor: Jong Woo Chung
The whole design needs to be revised. Recruiting --> Completed | N=56 --> 27 | Trial primary completion date: Sep 2015 --> Dec 2015
- Trial primary completion date: Study of the Efficacy of Topical Nasal Steroids Patients With Nasal Polyps (clinicaltrials.gov) - Feb 12, 2016
P=N/A, N=40, Recruiting, Sponsor: Loma Linda University
Recruiting --> Completed | N=56 --> 27 | Trial primary completion date: Sep 2015 --> Dec 2015 Trial primary completion date: Feb 2016 --> Feb 2017
- Trial completion, Phase classification, Trial primary completion date: Sinopsys Lacrimal Stent Indicated for Sinus Irrigation (clinicaltrials.gov) - Feb 12, 2016
P0, N=9, Completed, Sponsor: Sinopsys Surgical
Trial primary completion date: Feb 2016 --> Feb 2017 Active, not recruiting --> Completed | Phase classification: PN/A --> P0 | Trial primary completion date: Nov 2015 --> Feb 2016
- || mometasone furoate nasal spray / Generic mfg.
Phase classification, Surgery: Steroid-Releasing S8 Sinus Implant for Recurrent Nasal Polyps (clinicaltrials.gov) - Feb 10, 2016
P2/3, N=100, Completed, Sponsor: Intersect ENT
Active, not recruiting --> Completed | Phase classification: PN/A --> P0 | Trial primary completion date: Nov 2015 --> Feb 2016 Phase classification: P3 --> P2/3
- || AIMab7195 / Nestle
Enrollment closed: Safety and Tolerability of XmAb (clinicaltrials.gov) - Feb 10, 2016
P1, N=72, Active, not recruiting, Sponsor: Xencor, Inc.
Phase classification: P3 --> P2/3 Recruiting --> Active, not recruiting
- Trial primary completion date: Nasal Obstruction in Sleep Apnea Patients Compared to the General Population (clinicaltrials.gov) - Feb 9, 2016
P=N/A, N=200, Recruiting, Sponsor: Norwegian University of Science and Technology
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Dec 2016
- ||| Trial completion, Enrollment change, Trial primary completion date: Clinical Evaluation of a Novel Balance, Vestibular and Oculomotor Assessment Tool (clinicaltrials.gov) - Feb 9, 2016
P=N/A, N=126, Completed, Sponsor: Emory University
Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Completed | N=100 --> 126 | Trial primary completion date: Dec 2015 --> Sep 2015
- Enrollment change: Tongue Pressure Profile Training for Dysphagia Post Stroke (clinicaltrials.gov) - Feb 8, 2016
P2, N=14, Completed, Sponsor: Toronto Rehabilitation Institute
Recruiting --> Completed | N=100 --> 126 | Trial primary completion date: Dec 2015 --> Sep 2015 N=26 --> 14
- acetylcysteine solution / Generic mfg.
Enrollment closed, Enrollment change: Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy (clinicaltrials.gov) - Feb 5, 2016
P=N/A, N=18, Active, not recruiting, Sponsor: Mayo Clinic
N=26 --> 14 Recruiting --> Active, not recruiting | N=36 --> 18
- ||||||| Xhance (fluticasone propionate intranasal spray) / OptiNose
Trial completion: Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 ?g of Fluticasone Propionate Using a Novel Bi-directional Device (clinicaltrials.gov) - Feb 4, 2016
P3, N=323, Completed, Sponsor: Optinose US Inc.
Recruiting --> Active, not recruiting | N=36 --> 18 Active, not recruiting --> Completed
- ||||||| Xhance (fluticasone propionate intranasal spray) / OptiNose
Trial completion: 12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device (clinicaltrials.gov) - Feb 4, 2016
P3, N=223, Completed, Sponsor: Optinose US Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial primary completion date, Surgery: Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the Oral Cavity (clinicaltrials.gov) - Feb 4, 2016
P2, N=57, Not yet recruiting, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Trial primary completion date: Jan 2016 --> Jan 2017
- gevokizumab (VPM087) / Novartis
Trial completion: The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease (clinicaltrials.gov) - Feb 3, 2016
P2, N=10, Completed, Sponsor: XOMA (US) LLC
Trial primary completion date: Jan 2016 --> Jan 2017 Active, not recruiting --> Completed
- ||||||| Xhance (fluticasone propionate intranasal spray) / OptiNose
Trial completion: Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 ?g of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety (clinicaltrials.gov) - Feb 3, 2016
P3, N=323, Completed, Sponsor: Optinose US Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Phase classification, PD(L)-1 Biomarker, IO biomarker, Gene therapy: T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers (clinicaltrials.gov) - Feb 3, 2016
P2, N=61, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Phase classification: P1/2 --> P2
- | Trial completion, Trial primary completion date: The EarLens System Long Term Safety and Efficacy Definitive Multi-Center Study (clinicaltrials.gov) - Feb 2, 2016
P=N/A, N=48, Completed, Sponsor: EarLens Corporation
Phase classification: P1/2 --> P2 Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Jan 2015